- Home
- SIG vs VKTX Comparison
SIG vs VKTX Comparison
Compare SIG & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIG | VKTX |
|---|---|---|
| Founded | 1950 | 2012 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SIG | VKTX |
|---|---|---|
| Price | $88.34 | $37.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $108.14 | $87.07 |
| AVG Volume (30 Days) | 1.1M | ★ 2.9M |
| Earning Date | 12-02-2025 | 10-22-2025 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.42 | N/A |
| Revenue | ★ $6,821,100,000.00 | N/A |
| Revenue This Year | $2.81 | N/A |
| Revenue Next Year | $1.42 | N/A |
| P/E Ratio | $25.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $45.55 | $18.92 |
| 52 Week High | $110.20 | $49.67 |
Technical Indicators
Market Signals| Indicator | SIG | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 53.21 |
| Support Level | $82.52 | $36.49 |
| Resistance Level | $92.82 | $39.99 |
| Average True Range (ATR) | 4.62 | 1.88 |
| MACD | -0.33 | 0.01 |
| Stochastic Oscillator | 23.59 | 57.05 |
Price Performance
Historical ComparisonAbout SIG Signet Jewelers Limited
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Off-Mall & Outlet.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.